These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 26517758)

  • 1. Overcoming drug resistance for macro parasites.
    Srivastava M; Misra-Bhattacharya S
    Future Microbiol; 2015; 10(11):1783-9. PubMed ID: 26517758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A research agenda for helminth diseases of humans: intervention for control and elimination.
    Prichard RK; Basáñez MG; Boatin BA; McCarthy JS; García HH; Yang GJ; Sripa B; Lustigman S
    PLoS Negl Trop Dis; 2012; 6(4):e1549. PubMed ID: 22545163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foreword: towards markers for anthelmintic resistance in helminths of importance in animal and human health.
    Prichard RK; von Samson-Himmelstjerna G; Blackhall WJ; Geary TG
    Parasitology; 2007; 134(Pt 8):1073-6. PubMed ID: 17608966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular aspects of drug resistance in parasitic helminths.
    Roos MH; Kwa MS; Veenstra JG; Kooyman FN; Boersema JH
    Pharmacol Ther; 1993 Nov; 60(2):331-6. PubMed ID: 8022863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Will technology provide solutions for drug resistance in veterinary helminths?
    von Samson-Himmelstjerna G; Blackhall W
    Vet Parasitol; 2005 Sep; 132(3-4):223-39. PubMed ID: 16118040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug discovery technologies: Caenorhabditis elegans as a model for anthelmintic therapeutics.
    Sepúlveda-Crespo D; Reguera RM; Rojo-Vázquez F; Balaña-Fouce R; Martínez-Valladares M
    Med Res Rev; 2020 Sep; 40(5):1715-1753. PubMed ID: 32166776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance.
    Kerboeuf D; Blackhall W; Kaminsky R; von Samson-Himmelstjerna G
    Int J Antimicrob Agents; 2003 Sep; 22(3):332-46. PubMed ID: 13678840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility.
    Smout MJ; Kotze AC; McCarthy JS; Loukas A
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e885. PubMed ID: 21103363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drugs we have and the drugs we need against major helminth infections.
    Keiser J; Utzinger J
    Adv Parasitol; 2010; 73():197-230. PubMed ID: 20627144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Worms--a "license to kill".
    Kaminsky R; Rufener L; Bouvier J; Lizundia R; Schorderet Weber S; Sager H
    Vet Parasitol; 2013 Aug; 195(3-4):286-91. PubMed ID: 23664156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthelmintic drug discovery: into the future.
    Geary TG; Sakanari JA; Caffrey CR
    J Parasitol; 2015 Apr; 101(2):125-33. PubMed ID: 25584662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzimidazole resistance in helminths: From problem to diagnosis.
    Furtado LFV; de Paiva Bello ACP; Rabelo ÉML
    Acta Trop; 2016 Oct; 162():95-102. PubMed ID: 27338184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthelmintic resistance in human helminths: a review.
    Geerts S; Gryseels B
    Trop Med Int Health; 2001 Nov; 6(11):915-21. PubMed ID: 11703846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthelmintic drugs and nematicides: studies in Caenorhabditis elegans.
    Holden-Dye L; Walker RJ
    WormBook; 2014 Dec; ():1-29. PubMed ID: 25517625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods to sustain drug efficacy in helminth control programmes.
    Albonico M
    Acta Trop; 2003 May; 86(2-3):233-42. PubMed ID: 12745140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are new anthelmintics needed to eliminate human helminthiases?
    Geary TG
    Curr Opin Infect Dis; 2012 Dec; 25(6):709-17. PubMed ID: 23041774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using a health-rating system to evaluate the usefulness of Caenorhabditis elegans as a model for anthelmintic study.
    Weaver KJ; May CJ; Ellis BL
    PLoS One; 2017; 12(6):e0179376. PubMed ID: 28632749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing anthelmintic resistance: is it feasible in New Zealand to delay the emergence of resistance to a new anthelmintic class?
    Leathwick DM; Hosking BC; Bisset SA; McKay CH
    N Z Vet J; 2009 Aug; 57(4):181-92. PubMed ID: 19649011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventive Chemotherapy in the Fight against Soil-Transmitted Helminthiasis: Achievements and Limitations.
    Schulz JD; Moser W; Hürlimann E; Keiser J
    Trends Parasitol; 2018 Jul; 34(7):590-602. PubMed ID: 29858018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthelmintic resistance: past, present and future.
    Sangster NC
    Int J Parasitol; 1999 Jan; 29(1):115-24; discussion 137-8. PubMed ID: 10048824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.